monday.com Announces Participation in the 51st Nasdaq London Investor Conference
Get Alerts MNDY Hot Sheet
Join SI Premium – FREE
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)-- monday.com (NASDAQ: MNDY), the multi-product platform that runs all core aspects of work, today announced that members of its management team are scheduled to participate in the 51st Nasdaq London Investor Conference on Tuesday, December 10, 2024, at 1:30pm GMT.
The presentation will cover recent events in fireside chat format and will be webcast live on monday.com’s investor relations website at http://ir.monday.com. A replay of the presentation will be made available on the website under the News and Events section.
About monday.com:
The monday.com Work OS is a low code- no code platform that democratizes the power of software so organizations can easily build work management tools and software applications to fit their every need. The platform intuitively connects people to processes and systems, empowering teams to excel in every aspect of their work while creating an environment of transparency in business. monday.com has offices in Tel Aviv, New York, Denver, London, Warsaw, Sydney, Melbourne, São Paulo, and Tokyo. Fully customizable to suit any business vertical, the platform is currently used by over 225,000 customers across more than 200 industries and in over 200 countries and territories.
Visit us on our LinkedIn, X (formerly Twitter), Instagram, YouTube, TikTok, and Facebook. For more information about monday.com please visit our Press Room.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118348662/en/
Investor Relations:
Byron Stephen
[email protected]
Media Relations:
Julie Case
[email protected]
Source: monday.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 2026
- EFICAS Study Results Confirm the Clinical Performance of the Aeson® Total Artificial Heart as a Bridge-to-Transplant Therapy
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share